ONTOLOGY REPORT - ANNOTATIONS
| Term: | urethane |
|
| Accession: | CHEBI:17967
|
browse the term
|
| Definition: | A carbamate ester that has formula C3H7NO2. |
| Synonyms: | related_synonym: | C3H7NO2; CCOC(N)=O; Ethyl carbamate; InChI=1S/C3H7NO2/c1-2-6-3(4)5/h2H2,1H3,(H2,4,5); InChIKey=JOYRKODLDBILNP-UHFFFAOYSA-N; carbamic acid ethyl ester |
| | alt_id: | CHEBI:15295; CHEBI:27225; CHEBI:9892 |
| | xref_casrn: | 51-79-6 |
| | xref: | ChEMBL:552538 "ChEMBL COMPOUND"; DrugBank:DB04827 "DrugBank"; KEGG COMPOUND:51-79-6 "CAS Registry Number"; KEGG COMPOUND:C01537 "KEGG COMPOUND" |
| | xref_mesh: | MESH:D014520 |
|
|
urethane
|
| G |
Angpt2 |
angiopoietin 2 |
|
multiple interactions |
ISO |
16 |
75,891,757 |
75,942,255 |
RGD:6480464 |
CTD |
| G |
Anxa3 |
annexin A3 |
|
multiple interactions |
ISO |
14 |
14,245,112 |
14,297,100 |
RGD:6480464 |
CTD |
| G |
Anxa3 |
annexin A3 |
|
decreases expression |
ISO |
14 |
14,245,112 |
14,297,100 |
RGD:6480464 |
CTD |
| G |
Aqp1 |
aquaporin 1 |
|
decreases expression |
ISO |
4 |
84,098,346 |
84,110,524 |
RGD:6480464 |
CTD |
| G |
Atpif1 |
ATPase inhibitory factor 1 |
|
increases expression |
ISO |
5 |
152,618,307 |
152,622,024 |
RGD:6480464 |
CTD |
| G |
Bak1 |
BCL2-antagonist/killer 1 |
|
multiple interactions |
ISO |
20 |
5,255,954 |
5,264,593 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
decreases expression |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bid |
BH3 interacting domain death agonist |
|
multiple interactions |
ISO |
4 |
157,296,383 |
157,318,481 |
RGD:6480464 |
CTD |
| G |
Bik |
BCL2-interacting killer (apoptosis-inducing) |
|
increases expression |
EXP |
7 |
121,377,004 |
121,396,609 |
RGD:6480464 |
CTD |
| G |
Bmp4 |
bone morphogenetic protein 4 |
|
multiple interactions |
ISO |
15 |
22,283,171 |
22,286,757 |
RGD:6480464 |
CTD |
| G |
Casp12 |
caspase 12 |
|
decreases expression |
ISO |
8 |
2,082,933 |
2,110,511 |
RGD:6480464 |
CTD |
| G |
Casp2 |
caspase 2 |
|
increases expression |
EXP |
4 |
70,029,728 |
70,047,164 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases expression |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases expression |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
|
multiple interactions |
ISO |
10 |
71,605,791 |
71,610,330 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
multiple interactions |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccng1 |
cyclin G1 |
|
increases expression |
ISO |
10 |
25,776,380 |
25,782,754 |
RGD:6480464 |
CTD |
| G |
Cdk4 |
cyclin-dependent kinase 4 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cdk4 |
cyclin-dependent kinase 4 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
decreases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
decreases expression |
ISO |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
|
decreases expression |
ISO |
1 |
203,835,215 |
203,837,844 |
RGD:6480464 |
CTD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
decreases expression |
ISO |
5 |
108,908,749 |
108,916,380 |
RGD:6480464 |
CTD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
increases response to substance |
ISO |
5 |
108,908,749 |
108,916,380 |
RGD:6480464 |
CTD |
| G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) |
|
decreases expression |
ISO |
5 |
108,939,669 |
108,945,293 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
multiple interactions |
EXP |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
multiple interactions |
EXP |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Cidec |
cell death-inducing DFFA-like effector c |
|
decreases expression |
ISO |
4 |
149,307,986 |
149,321,303 |
RGD:6480464 |
CTD |
| G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
|
increases expression |
ISO |
2 |
181,611,639 |
181,616,222 |
RGD:6480464 |
CTD |
| G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
|
increases expression |
ISO |
17 |
19,423,502 |
19,429,451 |
RGD:6480464 |
CTD |
| G |
Cpd |
carboxypeptidase D |
|
decreases expression |
ISO |
10 |
67,327,272 |
67,390,836 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
decreases expression |
ISO |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Creb1 |
cAMP responsive element binding protein 1 |
|
multiple interactions |
ISO |
9 |
63,170,785 |
63,234,727 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
multiple interactions |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
multiple interactions |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
decreases metabolic processing |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
decreases response to substance |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
affects hydroxylation |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
affects metabolic processing |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
affects oxidation |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
increases response to substance |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
multiple interactions |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
affects metabolic processing |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
affects metabolic processing |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
affects metabolic processing |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
E2f1 |
E2F transcription factor 1 |
|
increases expression |
ISO |
3 |
145,032,489 |
145,043,729 |
RGD:6480464 |
CTD |
| G |
Ednrb |
endothelin receptor type B |
|
multiple interactions |
ISO |
15 |
87,893,141 |
87,898,700 |
RGD:6480464 |
CTD |
| G |
Ednrb |
endothelin receptor type B |
|
decreases expression |
ISO |
15 |
87,893,141 |
87,898,700 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
increases expression |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
increases expression |
ISO |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Elavl1 |
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) |
|
affects localization |
ISO |
12 |
1,459,046 |
1,500,042 |
RGD:6480464 |
CTD |
| G |
Elavl1 |
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) |
|
increases expression |
ISO |
12 |
1,459,046 |
1,500,042 |
RGD:6480464 |
CTD |
| G |
Fadd |
Fas (TNFRSF6)-associated via death domain |
|
multiple interactions |
ISO |
1 |
205,010,363 |
205,012,768 |
RGD:6480464 |
CTD |
| G |
Fasn |
fatty acid synthase |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Fbln5 |
fibulin 5 |
|
decreases expression |
ISO |
6 |
126,018,541 |
126,098,234 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
multiple interactions |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
increases secretion |
ISO |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Flt1 |
FMS-related tyrosine kinase 1 |
|
multiple interactions |
ISO |
12 |
7,858,092 |
8,035,966 |
RGD:6480464 |
CTD |
| G |
Flt1 |
FMS-related tyrosine kinase 1 |
|
increases expression |
ISO |
12 |
7,858,092 |
8,035,966 |
RGD:6480464 |
CTD |
| G |
Folr1 |
folate receptor 1 (adult) |
|
multiple interactions |
ISO |
1 |
159,315,191 |
159,324,141 |
RGD:6480464 |
CTD |
| G |
Folr1 |
folate receptor 1 (adult) |
|
multiple interactions |
ISO |
1 |
159,315,191 |
159,324,141 |
RGD:6480464 |
CTD |
| G |
Folr1 |
folate receptor 1 (adult) |
|
increases expression |
ISO |
1 |
159,315,191 |
159,324,141 |
RGD:6480464 |
CTD |
| G |
Folr2 |
folate receptor 2 (fetal) |
|
multiple interactions |
ISO |
1 |
159,295,773 |
159,314,107 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
decreases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Foxm1 |
forkhead box M1 |
|
affects response to substance |
ISO |
4 |
165,383,666 |
165,394,688 |
RGD:6480464 |
CTD |
| G |
Foxm1 |
forkhead box M1 |
|
increases expression |
ISO |
4 |
165,383,666 |
165,394,688 |
RGD:6480464 |
CTD |
| G |
Gabra1 |
gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
|
multiple interactions |
ISO |
10 |
27,258,813 |
27,313,725 |
RGD:6480464 |
CTD |
| G |
Gabrb2 |
gamma-aminobutyric acid (GABA) A receptor, beta 2 |
|
multiple interactions |
ISO |
10 |
27,602,085 |
27,819,145 |
RGD:6480464 |
CTD |
| G |
Gabrg2 |
gamma-aminobutyric acid (GABA) A receptor, gamma 2 |
|
multiple interactions |
ISO |
10 |
27,037,561 |
27,126,074 |
RGD:6480464 |
CTD |
| G |
Gast |
gastrin |
|
multiple interactions |
EXP |
10 |
89,273,628 |
89,276,192 |
RGD:6480464 |
CTD |
| G |
Gbp2 |
guanylate binding protein 2, interferon-inducible |
|
decreases expression |
ISO |
2 |
240,523,000 |
240,541,078 |
RGD:6480464 |
CTD |
| G |
Gh1 |
growth hormone 1 |
|
multiple interactions |
ISO |
10 |
95,692,240 |
95,694,117 |
RGD:6480464 |
CTD |
| G |
Gja1 |
gap junction protein, alpha 1 |
|
affects expression |
ISO |
20 |
35,409,815 |
35,422,262 |
RGD:6480464 |
CTD |
| G |
Gja3 |
gap junction protein, alpha 3 |
|
decreases expression |
ISO |
15 |
36,052,554 |
36,078,001 |
RGD:6480464 |
CTD |
| G |
Gjb1 |
gap junction protein, beta 1 |
|
decreases expression |
ISO |
X |
89,448,873 |
89,456,812 |
RGD:6480464 |
CTD |
| G |
Gjb2 |
gap junction protein, beta 2 |
|
decreases expression |
ISO |
15 |
36,153,526 |
36,159,490 |
RGD:6480464 |
CTD |
| G |
Gria1 |
glutamate receptor, ionotropic, AMPA 1 |
|
multiple interactions |
EXP |
10 |
42,613,359 |
42,616,610 |
RGD:6480464 |
CTD |
| G |
Gria2 |
glutamate receptor, ionotropic, AMPA 2 |
|
multiple interactions |
EXP |
2 |
172,265,155 |
172,385,285 |
RGD:6480464 |
CTD |
| G |
Grin1 |
glutamate receptor, ionotropic, N-methyl D-aspartate 1 |
|
multiple interactions |
ISO |
3 |
3,453,784 |
3,480,381 |
RGD:6480464 |
CTD |
| G |
Grin2a |
glutamate receptor, ionotropic, N-methyl D-aspartate 2A |
|
multiple interactions |
ISO |
10 |
5,588,229 |
6,004,780 |
RGD:6480464 |
CTD |
| G |
Gsn |
gelsolin |
|
decreases expression |
ISO |
3 |
14,360,245 |
14,386,313 |
RGD:6480464 |
CTD |
| G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
|
increases expression |
ISO |
4 |
79,700,327 |
79,704,116 |
RGD:6480464 |
CTD |
| G |
Hnrpd |
heterogeneous nuclear ribonucleoprotein D |
|
affects localization |
ISO |
14 |
10,917,674 |
10,935,989 |
RGD:6480464 |
CTD |
| G |
Hnrpd |
heterogeneous nuclear ribonucleoprotein D |
|
increases expression |
ISO |
14 |
10,917,674 |
10,935,989 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
multiple interactions |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases mutagenesis |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases response to substance |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases response to substance |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
multiple interactions |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases mutagenesis |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases response to substance |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases expression |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
decreases expression |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
multiple interactions |
ISO |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
multiple interactions |
ISO |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Igf2 |
insulin-like growth factor 2 |
|
multiple interactions |
ISO |
1 |
202,906,624 |
202,915,231 |
RGD:6480464 |
CTD |
| G |
Igf2 |
insulin-like growth factor 2 |
|
multiple interactions |
ISO |
1 |
202,906,624 |
202,915,231 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
multiple interactions |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
decreases expression |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il12a |
interleukin 12A |
|
multiple interactions |
ISO |
2 |
158,710,261 |
158,717,689 |
RGD:6480464 |
CTD |
| G |
Il12b |
interleukin 12B |
|
multiple interactions |
ISO |
10 |
29,558,955 |
29,568,331 |
RGD:6480464 |
CTD |
| G |
Il15 |
interleukin 15 |
|
multiple interactions |
ISO |
19 |
27,487,268 |
27,498,973 |
RGD:6480464 |
CTD |
| G |
Il15 |
interleukin 15 |
|
increases expression |
ISO |
19 |
27,487,268 |
27,498,973 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
multiple interactions |
ISO |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
decreases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
decreases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
multiple interactions |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
multiple interactions |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
multiple interactions |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
increases expression |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
increases expression |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
multiple interactions |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
decreases expression |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Inha |
inhibin alpha |
|
multiple interactions |
ISO |
9 |
74,781,223 |
74,784,124 |
RGD:6480464 |
CTD |
| G |
Inha |
inhibin alpha |
|
increases expression |
ISO |
9 |
74,781,223 |
74,784,124 |
RGD:6480464 |
CTD |
| G |
Itga1 |
integrin, alpha 1 |
|
multiple interactions |
ISO |
2 |
47,107,849 |
47,206,261 |
RGD:6480464 |
CTD |
| G |
Itga1 |
integrin, alpha 1 |
|
decreases expression |
ISO |
2 |
47,107,849 |
47,206,261 |
RGD:6480464 |
CTD |
| G |
Jak2 |
Janus kinase 2 |
|
multiple interactions |
ISO |
1 |
232,915,995 |
232,974,763 |
RGD:6480464 |
CTD |
| G |
Jak2 |
Janus kinase 2 |
|
increases expression |
ISO |
1 |
232,915,995 |
232,974,763 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
decreases expression |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Junb |
jun B proto-oncogene |
|
increases expression |
ISO |
19 |
24,831,536 |
24,833,320 |
RGD:6480464 |
CTD |
| G |
Kdr |
kinase insert domain receptor |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Kdr |
kinase insert domain receptor |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
affects response to substance |
ISO |
4 |
182,869,242 |
182,895,106 |
RGD:6480464 |
CTD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
decreases expression |
ISO |
4 |
182,869,242 |
182,895,106 |
RGD:6480464 |
CTD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
increases mutagenesis |
EXP |
4 |
182,869,242 |
182,895,106 |
RGD:6480464 |
CTD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
increases mutagenesis |
ISO |
4 |
182,869,242 |
182,895,106 |
RGD:6480464 |
CTD |
| G |
Map3k1 |
mitogen activated protein kinase kinase kinase 1 |
|
multiple interactions |
ISO |
2 |
43,062,252 |
43,126,058 |
RGD:6480464 |
CTD |
| G |
Map3k1 |
mitogen activated protein kinase kinase kinase 1 |
|
multiple interactions |
ISO |
2 |
43,062,252 |
43,126,058 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases activity |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases activity |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mdm2 |
p53 E3 ubiquitin protein ligase |
|
multiple interactions |
ISO |
7 |
56,996,694 |
57,020,926 |
RGD:6480464 |
CTD |
| G |
Mki67 |
antigen identified by monoclonal antibody Ki-67 |
|
multiple interactions |
ISO |
1 |
195,310,027 |
195,336,224 |
RGD:6480464 |
CTD |
| G |
Mki67 |
antigen identified by monoclonal antibody Ki-67 |
|
affects expression |
ISO |
1 |
195,310,027 |
195,336,224 |
RGD:6480464 |
CTD |
| G |
Mmp10 |
matrix metallopeptidase 10 (stromelysin 2) |
|
increases expression |
ISO |
8 |
4,367,842 |
4,375,737 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
multiple interactions |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
decreases expression |
ISO |
3 |
155,985,473 |
155,993,433 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
ISO |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases expression |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myo1b |
myosin Ib |
|
decreases expression |
ISO |
9 |
46,756,678 |
46,917,169 |
RGD:6480464 |
CTD |
| G |
Nars |
asparaginyl-tRNA synthetase |
|
increases expression |
ISO |
18 |
60,719,399 |
60,736,058 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
decreases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
multiple interactions |
ISO |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
increases expression |
ISO |
4 |
6,158,847 |
6,179,441 |
RGD:6480464 |
CTD |
| G |
Odc1 |
ornithine decarboxylase 1 |
|
multiple interactions |
ISO |
6 |
41,309,211 |
41,315,796 |
RGD:6480464 |
CTD |
| G |
Odc1 |
ornithine decarboxylase 1 |
|
increases activity |
ISO |
6 |
41,309,211 |
41,315,796 |
RGD:6480464 |
CTD |
| G |
Pam |
peptidylglycine alpha-amidating monooxygenase |
|
decreases expression |
ISO |
9 |
96,893,071 |
97,047,523 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
increases expression |
ISO |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
multiple interactions |
ISO |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
increases expression |
ISO |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
multiple interactions |
ISO |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
increases expression |
ISO |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pdgfa |
platelet-derived growth factor alpha polypeptide |
|
multiple interactions |
ISO |
12 |
16,151,045 |
16,172,412 |
RGD:6480464 |
CTD |
| G |
Pdgfb |
platelet-derived growth factor beta polypeptide |
|
multiple interactions |
ISO |
7 |
118,244,385 |
118,262,021 |
RGD:6480464 |
CTD |
| G |
Pias1 |
protein inhibitor of activated STAT, 1 |
|
multiple interactions |
ISO |
8 |
67,025,248 |
67,123,016 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases secretion |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Prdx3 |
peroxiredoxin 3 |
|
increases expression |
ISO |
1 |
267,468,371 |
267,481,273 |
RGD:6480464 |
CTD |
| G |
Prf1 |
perforin 1 (pore forming protein) |
|
decreases expression |
ISO |
20 |
28,658,367 |
28,663,877 |
RGD:6480464 |
CTD |
| G |
Prf1 |
perforin 1 (pore forming protein) |
|
multiple interactions |
ISO |
20 |
28,658,367 |
28,663,877 |
RGD:6480464 |
CTD |
| G |
Prkca |
protein kinase C, alpha |
|
multiple interactions |
ISO |
10 |
97,367,196 |
97,638,910 |
RGD:6480464 |
CTD |
| G |
Prkca |
protein kinase C, alpha |
|
decreases expression |
ISO |
10 |
97,367,196 |
97,638,910 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Ptger1 |
prostaglandin E receptor 1 (subtype EP1) |
|
increases expression |
ISO |
19 |
26,160,729 |
26,163,156 |
RGD:6480464 |
CTD |
| G |
Ptger1 |
prostaglandin E receptor 1 (subtype EP1) |
|
multiple interactions |
ISO |
19 |
26,160,729 |
26,163,156 |
RGD:6480464 |
CTD |
| G |
Ptger1 |
prostaglandin E receptor 1 (subtype EP1) |
|
multiple interactions |
ISO |
19 |
26,160,729 |
26,163,156 |
RGD:6480464 |
CTD |
| G |
Ptger2 |
prostaglandin E receptor 2 (subtype EP2) |
|
multiple interactions |
ISO |
15 |
20,205,443 |
20,216,872 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
increases expression |
ISO |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases expression |
EXP |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
decreases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Raf1 |
v-raf-leukemia viral oncogene 1 |
|
multiple interactions |
ISO |
4 |
151,752,583 |
151,775,609 |
RGD:6480464 |
CTD |
| G |
Rb1 |
retinoblastoma 1 |
|
decreases expression |
ISO |
15 |
53,828,881 |
53,962,099 |
RGD:6480464 |
CTD |
| G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
|
decreases expression |
ISO |
5 |
60,341,438 |
60,407,710 |
RGD:6480464 |
CTD |
| G |
Rel |
v-rel reticuloendotheliosis viral oncogene homolog (avian) |
|
increases expression |
ISO |
14 |
104,645,370 |
104,671,275 |
RGD:6480464 |
CTD |
| G |
Rel |
v-rel reticuloendotheliosis viral oncogene homolog (avian) |
|
multiple interactions |
ISO |
14 |
104,645,370 |
104,671,275 |
RGD:6480464 |
CTD |
| G |
Rpl23 |
ribosomal protein L23 |
|
increases expression |
ISO |
10 |
86,527,589 |
86,531,549 |
RGD:6480464 |
CTD |
| G |
Rpl32 |
ribosomal protein L32 |
|
increases expression |
ISO |
4 |
151,941,599 |
151,945,012 |
RGD:6480464 |
CTD |
| G |
Rps13 |
ribosomal protein S13 |
|
increases expression |
ISO |
1 |
174,425,813 |
174,428,243 |
RGD:6480464 |
CTD |
| G |
Rps20 |
ribosomal protein S20 |
|
increases expression |
ISO |
5 |
17,119,797 |
17,120,959 |
RGD:6480464 |
CTD |
| G |
Sardh |
sarcosine dehydrogenase |
|
increases expression |
ISO |
3 |
6,076,166 |
6,142,565 |
RGD:6480464 |
CTD |
| G |
Snurf |
SNRPN upstream reading frame |
|
decreases expression |
ISO |
1 |
111,576,073 |
111,592,853 |
RGD:6480464 |
CTD |
| G |
Spp1 |
secreted phosphoprotein 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
decreases expression |
ISO |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Tac1 |
tachykinin, precursor 1 |
|
multiple interactions |
EXP |
4 |
32,649,666 |
32,657,632 |
RGD:6480464 |
CTD |
| G |
Tagln2 |
transgelin 2 |
|
decreases expression |
ISO |
13 |
88,505,258 |
88,512,178 |
RGD:6480464 |
CTD |
| G |
Tek |
TEK tyrosine kinase, endothelial |
|
increases expression |
ISO |
5 |
115,047,195 |
115,196,172 |
RGD:6480464 |
CTD |
| G |
Tek |
TEK tyrosine kinase, endothelial |
|
multiple interactions |
ISO |
5 |
115,047,195 |
115,196,172 |
RGD:6480464 |
CTD |
| G |
Tep1 |
telomerase associated protein 1 |
|
multiple interactions |
ISO |
15 |
26,802,624 |
26,852,308 |
RGD:6480464 |
CTD |
| G |
Tep1 |
telomerase associated protein 1 |
|
increases expression |
ISO |
15 |
26,802,624 |
26,852,308 |
RGD:6480464 |
CTD |
| G |
Terc |
telomerase RNA component |
|
multiple interactions |
ISO |
2 |
117,234,446 |
117,234,833 |
RGD:6480464 |
CTD |
| G |
Tert |
telomerase reverse transcriptase |
|
multiple interactions |
ISO |
1 |
30,445,180 |
30,465,942 |
RGD:6480464 |
CTD |
| G |
Tert |
telomerase reverse transcriptase |
|
increases expression |
ISO |
1 |
30,445,180 |
30,465,942 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
affects response to substance |
ISO |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
decreases response to substance |
ISO |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
decreases expression |
ISO |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb2 |
transforming growth factor, beta 2 |
|
multiple interactions |
ISO |
13 |
102,718,703 |
102,818,768 |
RGD:6480464 |
CTD |
| G |
Tgfb2 |
transforming growth factor, beta 2 |
|
decreases expression |
ISO |
13 |
102,718,703 |
102,818,768 |
RGD:6480464 |
CTD |
| G |
Tgfb3 |
transforming growth factor, beta 3 |
|
multiple interactions |
ISO |
6 |
110,173,443 |
110,195,215 |
RGD:6480464 |
CTD |
| G |
Tgfb3 |
transforming growth factor, beta 3 |
|
decreases expression |
ISO |
6 |
110,173,443 |
110,195,215 |
RGD:6480464 |
CTD |
| G |
Tgfb3 |
transforming growth factor, beta 3 |
|
multiple interactions |
ISO |
6 |
110,173,443 |
110,195,215 |
RGD:6480464 |
CTD |
| G |
Tgfb3 |
transforming growth factor, beta 3 |
|
decreases expression |
ISO |
6 |
110,173,443 |
110,195,215 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
multiple interactions |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
|
multiple interactions |
ISO |
10 |
108,310,473 |
108,358,821 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
decreases expression |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tpm1 |
tropomyosin 1, alpha |
|
decreases expression |
ISO |
8 |
71,331,304 |
71,358,063 |
RGD:6480464 |
CTD |
| G |
Traf3 |
Tnf receptor-associated factor 3 |
|
increases expression |
EXP |
6 |
135,925,375 |
136,027,270 |
RGD:6480464 |
CTD |
| G |
Tspan7 |
tetraspanin 7 |
|
decreases expression |
ISO |
X |
24,362,332 |
24,383,176 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
increases secretion |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfc |
vascular endothelial growth factor C |
|
multiple interactions |
ISO |
16 |
40,624,435 |
40,739,692 |
RGD:6480464 |
CTD |
| G |
Vegfc |
vascular endothelial growth factor C |
|
increases expression |
ISO |
16 |
40,624,435 |
40,739,692 |
RGD:6480464 |
CTD |
| G |
Wee1 |
wee 1 homolog (S. pombe) |
|
multiple interactions |
ISO |
1 |
167,769,797 |
167,788,199 |
RGD:6480464 |
CTD |
Term paths to the root
|